Persistence with statin therapy in Hungary

Zoltan Kiss, Laszlo Nagy, Istvan Reiber, G. Paragh, Mark Peter Molnar, György Rokszin, Zsolt Abonyi-Toth, Laszlo Mark

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: Persistence with lipid-lowering drug therapy by cardiovascular patients in Hungary has not been studied previously. This study was designed to determine the rate with which Hungarian patients with hyperlipidemia persist in taking lipid-lowering agents, and to compare this with rates reported from other countries. Material and methods: This was a retrospective study that utilized data from the Institutional Database of the National Health Insurance Fund to analyze persistence rates with statins and ezetimibe. The study included data for patients who started lipid-lowering therapy between January 1, 2007, and March 31, 2009. Variables included type of lipid-lowering therapy, year of therapy start, and patient age. Main outcome measures were medians of persistence in months, percentages of patients persisting in therapy for 6 and 12 months, and Kaplan-Meier persistence plots. Results: The percentage of patients who persisted with overall statin therapy was 46% after 1 month, 40.3% after 2 months, 27% after 6 months, and 20.1% after 12 months. Persistence was slightly greater for statin therapy started during 2008 than during 2007. Older patients were more persistent with therapy than younger patients. Persistence with the combination of ezetimibe-statin therapy was greater than with statin or ezetimibe monotherapy. Conclusions: Persistence with statin therapy by patients in Hungary was low compared with other countries. Low persistence may have negated potential clinical benefits of long-term statin therapy.

Original languageEnglish
Pages (from-to)409-417
Number of pages9
JournalArchives of Medical Science
Volume9
Issue number3
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hungary
Lipids
Therapeutics
National Health Programs
Hyperlipidemias
Retrospective Studies
Outcome Assessment (Health Care)
Databases

Keywords

  • Adherence
  • Ezetimibe
  • Hungary
  • Persistence
  • Statins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kiss, Z., Nagy, L., Reiber, I., Paragh, G., Molnar, M. P., Rokszin, G., ... Mark, L. (2013). Persistence with statin therapy in Hungary. Archives of Medical Science, 9(3), 409-417. https://doi.org/10.5114/aoms.2013.35327

Persistence with statin therapy in Hungary. / Kiss, Zoltan; Nagy, Laszlo; Reiber, Istvan; Paragh, G.; Molnar, Mark Peter; Rokszin, György; Abonyi-Toth, Zsolt; Mark, Laszlo.

In: Archives of Medical Science, Vol. 9, No. 3, 06.2013, p. 409-417.

Research output: Contribution to journalArticle

Kiss, Z, Nagy, L, Reiber, I, Paragh, G, Molnar, MP, Rokszin, G, Abonyi-Toth, Z & Mark, L 2013, 'Persistence with statin therapy in Hungary', Archives of Medical Science, vol. 9, no. 3, pp. 409-417. https://doi.org/10.5114/aoms.2013.35327
Kiss Z, Nagy L, Reiber I, Paragh G, Molnar MP, Rokszin G et al. Persistence with statin therapy in Hungary. Archives of Medical Science. 2013 Jun;9(3):409-417. https://doi.org/10.5114/aoms.2013.35327
Kiss, Zoltan ; Nagy, Laszlo ; Reiber, Istvan ; Paragh, G. ; Molnar, Mark Peter ; Rokszin, György ; Abonyi-Toth, Zsolt ; Mark, Laszlo. / Persistence with statin therapy in Hungary. In: Archives of Medical Science. 2013 ; Vol. 9, No. 3. pp. 409-417.
@article{fdaad54affdf4b498ed54e57db65d845,
title = "Persistence with statin therapy in Hungary",
abstract = "Introduction: Persistence with lipid-lowering drug therapy by cardiovascular patients in Hungary has not been studied previously. This study was designed to determine the rate with which Hungarian patients with hyperlipidemia persist in taking lipid-lowering agents, and to compare this with rates reported from other countries. Material and methods: This was a retrospective study that utilized data from the Institutional Database of the National Health Insurance Fund to analyze persistence rates with statins and ezetimibe. The study included data for patients who started lipid-lowering therapy between January 1, 2007, and March 31, 2009. Variables included type of lipid-lowering therapy, year of therapy start, and patient age. Main outcome measures were medians of persistence in months, percentages of patients persisting in therapy for 6 and 12 months, and Kaplan-Meier persistence plots. Results: The percentage of patients who persisted with overall statin therapy was 46{\%} after 1 month, 40.3{\%} after 2 months, 27{\%} after 6 months, and 20.1{\%} after 12 months. Persistence was slightly greater for statin therapy started during 2008 than during 2007. Older patients were more persistent with therapy than younger patients. Persistence with the combination of ezetimibe-statin therapy was greater than with statin or ezetimibe monotherapy. Conclusions: Persistence with statin therapy by patients in Hungary was low compared with other countries. Low persistence may have negated potential clinical benefits of long-term statin therapy.",
keywords = "Adherence, Ezetimibe, Hungary, Persistence, Statins",
author = "Zoltan Kiss and Laszlo Nagy and Istvan Reiber and G. Paragh and Molnar, {Mark Peter} and Gy{\"o}rgy Rokszin and Zsolt Abonyi-Toth and Laszlo Mark",
year = "2013",
month = "6",
doi = "10.5114/aoms.2013.35327",
language = "English",
volume = "9",
pages = "409--417",
journal = "Archives of Medical Science",
issn = "1734-1922",
publisher = "Termedia Publishing House Ltd.",
number = "3",

}

TY - JOUR

T1 - Persistence with statin therapy in Hungary

AU - Kiss, Zoltan

AU - Nagy, Laszlo

AU - Reiber, Istvan

AU - Paragh, G.

AU - Molnar, Mark Peter

AU - Rokszin, György

AU - Abonyi-Toth, Zsolt

AU - Mark, Laszlo

PY - 2013/6

Y1 - 2013/6

N2 - Introduction: Persistence with lipid-lowering drug therapy by cardiovascular patients in Hungary has not been studied previously. This study was designed to determine the rate with which Hungarian patients with hyperlipidemia persist in taking lipid-lowering agents, and to compare this with rates reported from other countries. Material and methods: This was a retrospective study that utilized data from the Institutional Database of the National Health Insurance Fund to analyze persistence rates with statins and ezetimibe. The study included data for patients who started lipid-lowering therapy between January 1, 2007, and March 31, 2009. Variables included type of lipid-lowering therapy, year of therapy start, and patient age. Main outcome measures were medians of persistence in months, percentages of patients persisting in therapy for 6 and 12 months, and Kaplan-Meier persistence plots. Results: The percentage of patients who persisted with overall statin therapy was 46% after 1 month, 40.3% after 2 months, 27% after 6 months, and 20.1% after 12 months. Persistence was slightly greater for statin therapy started during 2008 than during 2007. Older patients were more persistent with therapy than younger patients. Persistence with the combination of ezetimibe-statin therapy was greater than with statin or ezetimibe monotherapy. Conclusions: Persistence with statin therapy by patients in Hungary was low compared with other countries. Low persistence may have negated potential clinical benefits of long-term statin therapy.

AB - Introduction: Persistence with lipid-lowering drug therapy by cardiovascular patients in Hungary has not been studied previously. This study was designed to determine the rate with which Hungarian patients with hyperlipidemia persist in taking lipid-lowering agents, and to compare this with rates reported from other countries. Material and methods: This was a retrospective study that utilized data from the Institutional Database of the National Health Insurance Fund to analyze persistence rates with statins and ezetimibe. The study included data for patients who started lipid-lowering therapy between January 1, 2007, and March 31, 2009. Variables included type of lipid-lowering therapy, year of therapy start, and patient age. Main outcome measures were medians of persistence in months, percentages of patients persisting in therapy for 6 and 12 months, and Kaplan-Meier persistence plots. Results: The percentage of patients who persisted with overall statin therapy was 46% after 1 month, 40.3% after 2 months, 27% after 6 months, and 20.1% after 12 months. Persistence was slightly greater for statin therapy started during 2008 than during 2007. Older patients were more persistent with therapy than younger patients. Persistence with the combination of ezetimibe-statin therapy was greater than with statin or ezetimibe monotherapy. Conclusions: Persistence with statin therapy by patients in Hungary was low compared with other countries. Low persistence may have negated potential clinical benefits of long-term statin therapy.

KW - Adherence

KW - Ezetimibe

KW - Hungary

KW - Persistence

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84879815554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879815554&partnerID=8YFLogxK

U2 - 10.5114/aoms.2013.35327

DO - 10.5114/aoms.2013.35327

M3 - Article

VL - 9

SP - 409

EP - 417

JO - Archives of Medical Science

JF - Archives of Medical Science

SN - 1734-1922

IS - 3

ER -